pharma · No medical condition. · Generalized Myasthenia Gravis
Lacuna Pharma Pty Ltd
Lacuna Pharma Pty is a pharma organization headquartered in Colmenar Viejo, AU. Primary therapeutic focus areas include No medical condition., Generalized Myasthenia Gravis, No therapeutic indication in the current trial
Phase 3 · small molecule · Acromegaly
Paltusotine (PALSONIFY) is a small-molecule therapeutic developed by Lacuna Pharma Pty Ltd for the treatment of acromegaly, a rare endocrine disorder characterized by excessive growth hormone secretion. The program is currently in Phase 3 development, with an active randomized, controlled, multi-center study evaluating
Internal code CRN00808-09
Paltusotine (PALSONIFY) is a small-molecule therapeutic developed by Lacuna Pharma Pty Ltd for the treatment of acromegaly, a rare endocrine disorder characterized by excessive growth hormone secretion. The program is currently in Phase 3 development, with an active randomized, controlled, multi-center study evaluating safety and efficacy in acromegaly patients already treated with long-acting somatostatin receptor ligands. Paltusotine has achieved European regulatory approval as of April 23, 2026, marketed by Crinetics Pharmaceuticals Europe GmbH under the brand name PALSONIFY. The therapeutic class is systemic hormonal preparations (H01). The Phase 3 trial (NCT 2024-511925-71-00) represents a key clinical milestone designed to establish the drug's benefit in a defined patient population with prior somatostatin receptor ligand exposure. Lacuna Pharma's strategy appears focused on addressing unmet needs in acromegaly management, particularly in patients with inadequate control on existing therapies. The European approval represents a significant regulatory validation, though mechanism of action and specific molecular target details remain undisclosed in available documentation.
Acromegaly is a rare but serious endocrine disorder with significant morbidity and mortality if untreated, affecting approximately 40–70 individuals per million. Current standard-of-care therapies include somatostatin receptor ligands (SRLs), dopamine agonists, and growth hormone receptor antagonists, yet many patients experience inadequate disease control or develop resistance. The Phase 3 trial design—specifically enrolling patients already on long-acting SRLs—targets a clinically relevant population with documented unmet medical need. Paltusotine's European approval in 2026 validates its therapeutic potential and regulatory pathway, positioning it as a potential add-on or alternative therapy in the acromegaly treatment armamentarium. The competitive landscape includes established agents such as SOMAVERT (pegvisomant, Pfizer), SIGNIFOR (pasireotide), SOGROYA, and newer agents like SKYTROFA, indicating a moderately competitive market with room for differentiated therapies. The commercial significance is supported by the rare disease indication, which typically commands premium pricing and orphan drug incentives. Paltusotine's approval in Europe and ongoing Phase 3 development suggest Lacuna Pharma is pursuing global regulatory strategy, with potential for label expansion and market penetration in North America and other regions.
Drug Class: Systemic hormonal preparation (H01 therapeutic classification).
Modality: Small-molecule.
Mechanism of Action: Not yet disclosed in available documentation.
Molecular Target: Not yet disclosed in available documentation.
Route of Administration: Oral tablet formulation (20 mg strength documented).
Brand Name: PALSONIFY.
International Nonproprietary Name (INN): Paltusotine.
Related Therapies: Paltusotine is positioned within the acromegaly treatment landscape alongside somatostatin receptor ligands (e.g., SIGNIFOR), growth hormone receptor antagonists (e.g., SOMAVERT), and newer agents (e.g., SKYTROFA). The Phase 3 trial design indicates potential use as adjunctive therapy in patients with inadequate response to long-acting SRLs.
First Approval: European Union approval granted April 23, 2026 (EMEA/H/C/006636), marketed by Crinetics Pharmaceuticals Europe GmbH.
Patent Status: Not yet disclosed.
Also known as: Growth hormone excess, pituitary giant, somatotroph adenoma
Prevalence: Point prevalence: 1-9 / 100 000 (Worldwide) — source: Orphanet, validated.
Acromegaly is an acquired disorder related to excessive production of growth hormone (GH) and characterized by progressive somatic disfigurement (mainly involving the face and extremities) and systemic manifestations.
ClinicalTrials.gov lists 9 registered studies for Growth Hormone (AACT aggregate).
Phase breakdown: NA (6), PHASE3 (2), PHASE2/PHASE3 (1)
Common investigational therapies:
Disease data sourced from MONDO Disease Ontology (MONDO:0019933), Orphanet — acromegaly, NCT00562796, NCT00966134, NCT01158612, NCT01540773, NCT04079010, AACT (ClinicalTrials.gov aggregate), ClinicalTrials.gov, Open Targets Platform (CC BY 4.0).
Phase 3 ongoing
Randomized, controlled, multi-center study evaluating safety and efficacy of paltusotine in acromegaly patients on long-acting somatostatin receptor ligands (NCT 2024-511925-71-00).
EMA approval
Paltusotine (PALSONIFY) approved by European Medicines Agency (EMEA/H/C/006636) for acromegaly; marketed by Crinetics Pharmaceuticals Europe GmbH.
The acromegaly treatment market includes multiple established and emerging therapies. SOMAVERT (pegvisomant, Pfizer) is a growth hormone receptor antagonist approved for acromegaly in patients inadequately controlled by other therapies. SIGNIFOR and SOGROYA represent somatostatin receptor ligand options. SKYTROFA (lonapegsomatropin, Ascendis Pharma) is a newer long-acting growth hormone preparation. NGENLA (Pfizer) and GENOTROPIN GOQUICK (Pfizer) are growth hormone formulations. Other agents such as INCRELEX, ORGOVYX, THYROGEN, ARX GANIRELIX, CETROTIDE, and YSELTY occupy various niches in endocrine and hormonal therapy. Paltusotine's Phase 3 trial design—targeting patients with inadequate control on long-acting SRLs—suggests positioning as an adjunctive or alternative agent for SRL-resistant disease. The European approval as of April 2026 provides regulatory validation and potential first-mover advantage in certain markets. Competitive differentiation likely depends on efficacy, safety profile, tolerability, and ease of administration relative to existing options, though specific comparative data are not yet disclosed.
| Therapy | Company | Mechanism | Status |
|---|---|---|---|
| INCRELEX | Lacuna Pharma Pty Ltd | — | approved |
| ORGOVYX | — | — | approved |
| THYROGEN | Sanofi-aventis Healthcare Pty Ltd | — | approved |
| SOMAVERT | Pfizer Australia Pty Ltd | — | approved |
| GENOTROPIN GOQUICK | Pfizer Australia Pty Ltd | — | approved |
| SIGNIFOR | — | — | approved |
| SOGROYA | — | — | approved |
| ARX GANIRELIX | Alphapharm Pty Ltd | — | approved |
| NGENLA | Pfizer Australia Pty Ltd | — | approved |
| CETROTIDE | Merck KGaA, Darmstadt, Germany | — | approved |
| YSELTY | — | — | approved |
| SKYTROFA (PREVIOUSLY LONAPEGSOMATROPIN ASCENDIS PHARMA) | — | — | approved |
| PEGVISOMANT | — | Growth hormone receptor antagonist | Approved |
| PASIREOTIDE PAMOATE | — | Somatostatin receptor 2 agonist | Approved |
| OCTREOTIDE ACETATE | — | Somatostatin receptor agonist | Approved |
| LANREOTIDE ACETATE | — | Somatostatin receptor 2 agonist | Approved |
| BROMOCRIPTINE MESYLATE | — | D2-like dopamine receptor agonist | Approved |
| PASIREOTIDE | — | Somatostatin receptor 5 agonist | Phase 3 |
| PALTUSOTINE | — | Somatostatin receptor 2 agonist | Phase 3 |
| OCTREOTIDE | — | Somatostatin receptor agonist | Phase 3 |
Additional associated therapies sourced from Open Targets Platform (CC0), linked to NovaPharmaNews drug profiles where matched.
European Union: Paltusotine (PALSONIFY) approved by the European Medicines Agency on April 23, 2026 (EMEA/H/C/006636). Marketing authorization holder: Crinetics Pharmaceuticals Europe GmbH.
United States (FDA): Regulatory status not yet disclosed.
Japan (PMDA): Regulatory status not yet disclosed.
China (NMPA): Regulatory status not yet disclosed.
Other Jurisdictions: Not yet disclosed.
The Phase 3 trial (NCT 2024-511925-71-00) is ongoing and may support future regulatory submissions in additional territories. Approval pathway and timing for other major markets remain to be disclosed.
Paltusotine is used for the treatment of acromegaly, a rare endocrine disorder characterized by excessive growth hormone secretion and abnormal body growth.
Yes, paltusotine (PALSONIFY) was approved by the European Medicines Agency on April 23, 2026. Regulatory status in other major markets such as the United States, Japan, and China is not yet disclosed.
Paltusotine is developed by Lacuna Pharma Pty Ltd. The European marketing authorization holder is Crinetics Pharmaceuticals Europe GmbH.
The brand name is PALSONIFY.
Paltusotine is available as a 20 mg tablet formulation.
Paltusotine is administered orally as a tablet. The specific dosing regimen is not yet disclosed in available documentation.
The mechanism of action of paltusotine is not yet disclosed in available documentation.
The specific molecular target is not yet disclosed in available documentation.
A Phase 3 randomized, controlled, multi-center study (NCT 2024-511925-71-00) is evaluating the safety and efficacy of paltusotine in acromegaly patients treated with long-acting somatostatin receptor ligands.
Paltusotine is in Phase 3 clinical development, with an ongoing randomized, controlled trial in acromegaly patients.
The Phase 3 trial targets acromegaly patients who are already being treated with long-acting somatostatin receptor ligands, indicating a focus on patients with inadequate control on existing therapy.
Paltusotine is classified as a systemic hormonal preparation (H01 therapeutic class).
Paltusotine is a small-molecule therapeutic.
Competitors include SOMAVERT (pegvisomant, Pfizer), SIGNIFOR (pasireotide), SOGROYA, SKYTROFA (lonapegsomatropin, Ascendis Pharma), and other hormonal and growth hormone therapies.
Paltusotine was approved by the European Medicines Agency on April 23, 2026, under the EMEA product number EMEA/H/C/006636.
Paltusotine addresses the unmet need of acromegaly patients with inadequate disease control on long-acting somatostatin receptor ligands, a population requiring additional or alternative therapeutic options.
CRN00808-09 → Drug → Target → Indication → Company → Trials → Competitors
Strategic Positioning: Lacuna Pharma's Phase 3 trial design targeting SRL-inadequate responders indicates a focused development strategy addressing a defined unmet need. European approval in April 2026 validates the therapeutic concept and provides regulatory precedent for other jurisdictions.
Competitive Implications: Paltusotine enters a moderately competitive acromegaly market with established players (Pfizer, Sanofi, Merck) and emerging therapies. Success will depend on demonstrated efficacy and safety advantages over existing options, particularly in the SRL-resistant population. The oral tablet formulation may offer convenience advantages over injectable competitors.
Development Catalysts: Completion and positive results of the Phase 3 trial (NCT 2024-511925-71-00) would be a critical catalyst. Regulatory submissions in the United States, Japan, and other major markets are anticipated but timing is not yet disclosed. Potential label expansions or additional indications may emerge post-approval.
Commercial Outlook: Acromegaly is a rare disease with limited patient populations but high treatment costs and orphan drug incentives. European approval provides market access and revenue generation potential. Global regulatory strategy and market penetration will determine long-term commercial success. Mechanism of action and comparative efficacy data remain key information gaps.
Concise, citable answers optimized for AI answer engines.
Intelligence compiled from public regulatory and clinical sources (FDA, EMA, ClinicalTrials.gov and company disclosures). Figures may be editorial or analyst estimates; verify against primary sources before relying on them.